Last update Aug. 21, 2014


High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Inhibitor of Epidermal Growth Factor receptor that acts by inhibition of tyrosine kinase phosphorylation and used for treatment of several types of cancer.

At latest update, relevant published data on excretion into breast milk were not found.

Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely.

If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½).

It means wait 15 days after the last dose before resuming breastfeeding.

Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.


We do not have alternatives for Erlotinib.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Erlotinib belongs to this group or family:


Main tradenames from several countries containing Erlotinib in its composition:


Variable Value Unit
Oral Bioavail. 59 %
Molecular weight 430 daltons
Protein Binding 93 %
VD 3.3 l/Kg
Tmax 4 hours
36 hours


  1. Erlotinib. Drug Summary 2014 Full text (link to original source) Full text (in our servers)
  2. EMEA Erlotinib. Ficha técnica 2012 Full text (in our servers)
  3. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM